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Case report
  Our patient, a 68-year-old Caucasian female, had a 4-
to-6-week history of  postmenopausal vaginal bleeding re-
quiring more than 2 pads per day. Pelvic ultrasound dem-
onstrated uterine prominence (8.6 cm x 6.1 cm x 4.9 cm) 
with thickening of  the endometrial complex (1.2 cm), as 
well as uterine fibroids (Fig. 1). An endometrial biopsy 
demonstrated diffuse large B-cell lymphoma, CD-20 posi-
tive (Fig. 2). FDG-18 PET/CT of  the skull to mid-thigh, 
performed for staging, demonstrated moderate FDG up-
take within the uterine endometrium with an SUV max of  
4.0 (Fig. 3). No other FDG-avid foci were evident. Bone-
marrow biopsy was morphologically and immunopheno-
typically negative for involvement by large B-cell lym-
phoma.
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We present a case of  primary endometrial B-cell lymphoma, pathologically confirmed.The patient is a 
68-year-old female with postmenopausal bleeding. Ultrasound revealed endometrial thickening and was 
followed up with endometrial biopsy.F18-FDG PET, performed for staging, demonstrated abnormally 
increased radiotracer uptake isolated to the endometrium.The patient was treated with chemotherapy 
(R-CHOP) and external-beam radiation. Endometrial activity was resolved on post-treatment followup 
F18-FDG PET. Primary endometrial lymphoid neoplasms are extremely rare (approximately 2% of  ex-
tranodal lymphoid neoplasms); even rarer is primary B-cell lymphoma. To our knowledge, this is the first 
reported case of  a successful treatment of  endometrial lymphoma using external-beam radiation and 
chemotherapy in a patient who did not receive hysterectomy. 
Citation: Revels J, Monteforte B, Malin D. Primary endometrial B-Cell lymphoma: 
Rare etiology of abnormal uterine bleeding and potential nonsurgical therapy. Radiol-
ogy Case Reports. (Online) 2015;10(1);1032.
Copyright: © 2015 The Authors. This is an open-access article distributed under the 
terms of the Creative Commons Attribution-NonCommercial-NoDerivs 2.5 License, 
which permits reproduction and distribution, provided the original work is properly 
cited. Commercial use and derivative works are not permitted.
The authors are all in the Department of Radiology, Eastern Virginia Medical School, 
Norfolk VA. Contact Dr. Revels at revels.DO@gmail.com.
Competing Interests:  The authors have declared that no competing interests exist.
DOI: 10.2484/rcr.v10i1.1032
Radiology Case Reports
Volume 10, Issue 1, 2015
Figure 1. A. Sagittal endovaginal grayscale sonographic 
image demonstrates endometrial thickening of 1.16cm. B. 
Sagittal endovaginal color Doppler image does not demon-
strate increased vascular flow.
The patient underwent three cycles of  systemic chemo-
therapy with combination Rituximab, Cyclophosphamide, 
Hydroxydaunorubicin, Oncovin, and Prednisone (R-
CHOP), followed by external-beam radiation therapy total-
ing 40Gy, delivered in 20 fractions.
A followup FDG-18 PET-CT scan 5 months after treat-
ment was negative (Fig. 4). As of  nine months post therapy, 
the patient remains asymptomatic and without signs of  
recurrence.
Discussion
 Primary, aggressive Non-Hodgkin’s lymphoma (NHL) of 
the uterus is an exceedingly rare cause of  postmenopausal 
bleeding, and there are few studies evaluating its manage-
ment. Past literature has suggested the use of  radical hys-
terectomy as a curative option for uterine NHL, but there 
remains limited data on the success of  nonsurgical methods 
(1-2). With respect to nonuterine NHL, chemotherapy with 
adjunctive external beam radiation has been proven effec-
tive, and is the standard of  treatment (3-5). Our patient 
demonstrates the potential for a nonsurgical, chemother-
apy- and radiation-based approach to curative uterine 
NHL treatment. 
The differential diagnosis for a patient with postmeno-
pausal bleeding includes endometrial atrophy (the most 
common cause), endometrial polyps, submucosal fibroids, 
endometrial hyperplasia, endometrial carcinoma, and es-
trogen withdrawal (6).At present, the American College of  
Obstetrics and Gynecology (ACOG) states that any patient 
with postmenopausal bleeding should receive malignancy 
workup with either endometrial biopsy or pelvic ultrasound 
(7). Reports comparing sonographic endometrial thickness 
to biopsy results in postmenopausal patients have demon-
strated that an endometrium of  less than 4-5mm has a 
negative predictive value for malignancy of  greater than 
99% (4, 5, 8). 
Levine et al evaluated endometrial thickness and its 
changes in postmenopausal patients using hormone re-
placement therapy (HRT) over a three-year period. They 
evaluated those patients on unopposed estrogen therapy, 
combined continuous estrogen and progesterone therapy, 
and sequential estrogen and progesterone therapy (estrogen 
is taken for days 1-25 and progesterone is taken on days 10-
25), and then compared these groups to a control group of  
patients not on HRT. The mean endometrial thicknesses 
were 5mm (+/- 2.9mm) in the control group, 6.6mm (+/- 
4mm) in the continuous unopposed estrogen group, 6.2mm 
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Figure 2. A. H&E-stained biopsy photomicrograph with cel-
lular atypia. B. Endometrial biopsy photomicrograph with 
CD-20 specific stain.
Figure 3. A. Sagittal fusion 18FDG PET/CT demonstrating 
focal increased activity within the endometrium. Incidental 
note is made of benign excreted FDG tracer in the bladder 
to the right of the uterus. B. Coronal fusion 18FDG PET/CT 
demonstrates focal increased activity within the en-
dometrium.
(+/- 2.4) in the dual therapy group, and 8.3mm (+/- 
3.9mm) in the sequential therapy group.Additionally, they 
recorded thickness changes during the study: 1-4mm (mean 
2mm) in the control group, 0-6mm (mean 2mm) in the con-
tinuous estrogen group, 1-9mm (mean 3mm) in the con-
tinuous combined therapy group, and 0-13mm (mean 
4mm) in the sequential therapy group (9).
Levine et al. did not establish guidelines regarding when 
to biopsy the presumably thickened endometrium. Instead, 
the biopsy decision was left to the discretion of  the manag-
ing physician and patient.Levine et al. concluded that fol-
lowup pelvic ultrasound should be performed before biopsy 
in patients without atypical uterine bleeding and in patients 
on sequential hormones because of  the normal physiologic 
endometrial changes. If  the repeated exam still demon-
strated thickness >8mm, then biopsy would be indicated. In 
patients on other hormone regimens, an endometrial thick-
ness > 8mm should be viewed as atypical, with biopsy indi-
cated. Abnormal uterine bleeding with an endometrial 
thickness of  5-8mm should call for biopsy as well. In the 
absence of  uterine bleeding, an endometrium of  5-8mm is 
considered probably normal (9).
The role of  PET/CT in the initial evaluation of  a pri-
mary endometrial malignancy is limited, as staging of  en-
dometrial cancer is primarily performed surgically: en-
dometrial biopsy, total abdominal hysterectomy, salpingo-
oopherectomy, pelvic and para-aortic lymph-node dissec-
tion, and peritoneal cytology (10). FDG PET is primarily 
used to evaluate for the extent of  disease. Use of  CT and 
MRI for assessment of  lymph-node involvement is unreli-
able (10). Grisby et al were able to detect pelvic and para-
aortic lymph-node metastasis with a sensitivity of  60% and 
a specificity of  98% in patients with uterine corpus malig-
nancy (10). Saga et al evaluated the use of  FDG PET in 
postoperative patients with endometrial cancer for recur-
rence of  disease or response to therapy and showed that, 
when coupled with anatomic information from CT or 
MRI, the sensitivity of  FDG PET was 100% and the 
specificity was 88%. Additionally, FDG PET had a high 
negative predictive value for exclusion of  recurrence (11).
Since primary endometrial lymphoma is rare, a clinical 
dilemma one will likely encounter when interpreting FDG 
PET is nonspecific endometrial activity. Lerman et al. 
evaluated 285 pre- and postmenopausal patients to deter-
mine normal and abnormal endometrial and ovarian up-
take of  F-18 FDG. They found that in premenopausal pa-
tients, SUV were 5 +/- 3.2 (SD) and 3.7 +/- 0.9 during 
menstruation and ovulating phases, respectively. The pro-
liferative and secretory phases were 2.6 +/- 1.1 and 2.5 
+/- 1.1 SUV, respectively. The mean SUV in postmeno-
pausal women on hormone replacement therapy was not 
significantly altered compared to those not on HRT: 1.7 
+/- 0.7. Therefore, increased endometrial activity in post-
menopausal women should be viewed as suspicious for 
malignancy (12).
Kitajima et al. reviewed FDG PET/CT findings in be-
nign and malignant tumors (uterine cervical cancer, en-
dometrial cancer, leiomyosarcoma, and other sarcomas 
such as endometrial stromal and uterine carcinosarcoma). 
Benign tumors generally show mild FDG uptake, for which 
the authors gave an example of  faint FDG activity with an 
SUV of  2. Activity in leiomyomas was seen in 10.4% of  
premenopausal patients and in only 1.2% of  postmeno-
pausal patients. Factors causing increased leiomyoma activ-
ity include those affecting normal endometrial activity in 
the premenopausal patient, as well as vascularity, cellularity, 
and inflammation.Adenomyosis is most affected during 
menstruation and ovulation. Additionally, endometrial hy-
perplasia can also demonstrate mildly increased activity. In 
general, malignant tumors demonstrate increased FDG 
activity. Exceptions to this include small tumors, beyond 
the spatial resolution of  PET imaging, and those of  low 
cellularity. High FDG activity can be seen in cervical can-
cers (squamous cell) with a mean SUV of  11.4, endome-
trial cancer with a mean SUV of  11.2 +/- 5.9, leimyosar-
coma with a mean SUV 6.4 +/- 4.3, and other malignan-
cies such as metastatic tumors, which also generally show 
intense FDG uptake. Because there is a potential overlap 
between leiomyosarcoma and leiomyoma, FDG PET can-
not be used to differentiate between the two (13).
Conclusion
Primary, aggressive Non-Hodgkin’s lymphoma (NHL) of  
the uterus is a rare cause of  postmenopausal bleeding and 
has imaging characteristics overlapping with other uterine 
malignancies.We report this case to broaden the differen-
tial diagnosis of  abnormal endometrial thickening and to 
highlight a nonsurgical-based treatment for primary NHL 
of  the endometrium.
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